purine synthesis enzymes Inhibitors
2 drugsAbout purine synthesis enzymes
Purine synthesis enzymes are essential for creating purines, the building blocks of DNA and RNA, catalyzing reactions crucial for cell growth and proliferation. These enzymes are attractive targets for drug development, particularly in oncology, due to their fundamental role in cell division.
While there is currently no genetic evidence directly linking these enzymes to specific diseases, their fundamental role in cell division highlights their therapeutic potential. Targeting these enzymes can disrupt cell growth, making them relevant in oncology and other areas where controlling cell proliferation is beneficial.
Two FDA-approved drugs, PURIXAN and PURINETHOL, target purine synthesis enzymes for cancer treatment, both are small molecules. These drugs, developed by NOVA LABS LTD and STASON PHARMS, demonstrate the viability of this approach in oncology.
Top purine synthesis enzymes Drugs
The competitive landscape includes two companies, NOVA LABS LTD and STASON PHARMS, with approved drugs.
Low market concentration suggests opportunities for new entrants, but high regulatory barriers exist.
purine synthesis enzymes Drug Modality Landscape
Modalities
Routes of Administration
purine synthesis enzymes is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
purine synthesis enzymes Clinical Trials 87 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on purine synthesis enzymes. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 5 | 2 | 9 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine synthesis enzymes Drug Approval Timeline (1953 - 2014)
The first drug was approved in 1953, and the most recent in 2014, spanning 62 years.
The long approval span indicates a mature target class, but recent approval suggests continued interest.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 39 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on purine synthesis enzymes. A trial counts if an approved drug acting on purine synthesis enzymes is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.